Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
You may also be interested in...
Start-Up Quarterly Statistics, Q2 2012
In the second quarter of 2012, start-up companies raised a total of $556 million across all industries. Most of that financing – $439.8 million – went to the biopharma sector. Cancer was the most prevalent therapeutic area for alliances. There were just four start-up acquisitions – two each in the biopharma and medical device industries.
For Some VCs And Execs, Familiarity Breeds More Start-Ups
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.
For Some VCs And Execs, Familiarity Breeds More Start-Ups
As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.